TME PHARMA PROVIDES UPDATE ON NUMBER OF OUTSTANDING SHARES AND WARRANTS FOLLOWING FIRST WARRANT Y EXERCISE PERIOD

- **974,365 Warrants Y exercised resulting in issuance of 389,746 new ordinary shares and 389,746 Warrants Z**

Berlin, Germany, January 23, 2024, 06.00 p.m. CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), provides an update on the outstanding number of ordinary shares, Warrants Y and Warrants Z following the exercise of 974,365 Warrants Y for €97,436.50 during the completion of the first Warrant Y exercise period.

In this first exercise period, from January 10-16, 2024, five Warrants Y entitled a holder to subscribe for two ABSA Z, each costing €0.25 and comprised of one ALTME share and one Warrant Z (Bon de souscription d'actions Z).

As a result of these exercises, 389,746 new ordinary shares and 389,746 Warrants Z were issued by *TME Pharma* and settled today. The following numbers of *TME Pharma* securities are thus issued and outstanding:

- ALTME ordinary shares (ISIN: NL0015000YE1): 17,710,591
- Warrants Y (ISIN : NL0015001SS1): 9,851,163
- Warrants Z (ISIN: NL0015001SR3): 389,746.

The second and final exercise period for the Warrants Y will run from February 12-16, 2024. Warrants Y that have not been exercised by the end of the exercise period at the latest will become null and void.

The first Warrant Z exercise period will run from February 26 to March 22, 2024, with settlement on March 29, 2024. Warrants Z may be exercised through June 2025.

Additional Information

The characteristics, terms and conditions and dilution resulting from the transaction are summarized in the press releases published on November 24 and November 28, 2023 and in the dedicated Rights Issue page on the *TME Pharma* website.

Dilution

The table below summarizes the dilution from the new ordinary shares issued today, and the maximum additional dilutive potential for an investor who did NOT participate in the transaction should all

remaining Warrants Y and all potential Warrants Z be exercised. Shareholders who participated fully in the transaction, i.e. who purchased the ABSA Y and subsequently exercise both Warrants Y and Z will not be diluted by this transaction.

Description	Shares to be issued	Total shares outstanding	Dilution (cumulative)	Shareholder starting with 1% on January 22, 2024, would then hold
Outstanding shares on January 22, 2024	-	17,320,845	-	1%
Shares issued on January 23, 2024, from exercise of 974,365 Warrants Y	389,746	17,710,591	2.20%	0.98%
Exercise of all remaining Warrants Y (latest on February 16, 2024)	3,940,465	21,651,056	20.00%	0.80%
Exercise of Warrants Z (latest on June 20, 2025)	5,412,764	27,063,820	36.00%	0.64%

For more information, please contact:

TME Pharma N.V.
Aram Mangasarian, Ph.D., CEO
Tel. +49 (0) 30 726247 0
investors@tmepharma.com

Investor and Media Relations:

LifeSci Advisors
Guillaume van Renterghem
Tel. +41 (0) 76 735 01 31
gvanrenterghem@lifesciadvisors.com

NewCap
Arthur Rouillé
Tel. +33 (0) 1 44 71 00 15
arouille@newcap.fr

About TME Pharma

TME Pharma is a clinical-stage company focused on developing novel therapies for treatment of the most aggressive cancers. The company's oncology-focused pipeline is designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair. By neutralizing chemokines in the TME, *TME Pharma's* approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. In the GLORIA clinical trial, *TME Pharma* is studying its lead drug candidate NOX-A12 in newly diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy. *TME Pharma* has delivered top-line data from the NOX-A12 three dose-escalation cohorts combined with radiotherapy of the GLORIA clinical trial, observing consistent tumor reductions and objective tumor responses. Additionally, GLORIA expansion arms evaluate safety and efficacy of NOX-A12 in other combinations where the interim results from the triple combination of NOX-A12, radiotherapy and bevacizumab suggest even deeper and more durable responses, and improved survival. NOX-A12 in combination with radiotherapy has received orphan drug designation for glioblastoma in the United States and glioma in Europe. *TME Pharma* has delivered final top-line data with encouraging overall survival and safety profile from its NOX-A12 combination trial with Keytruda® in metastatic colorectal and pancreatic cancer patients, which was published in the Journal for ImmunoTherapy of Cancer in October 2021. The company has entered in its second collaboration with MSD/Merck for its Phase 2 study, OPTIMUS, to further evaluate safety and efficacy of NOX-A12 in combination with Merck's Keytruda® and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. The design of the trial has been approved in France, Spain and the United States. The company's second clinical-stage drug candidate, NOX-E36, is designed to target the innate immune system. *TME Pharma* is considering several solid tumors for further clinical development. Further information can be found at: www.tmepharma.com.

Visit *TME Pharma* on LinkedIn and Twitter.

About the GLORIA Study

GLORIA (NCT04121455) is *TME Pharma's* dose-escalation, Phase 1/2 study of NOX-A12 in combination with radiotherapy in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy). GLORIA further evaluates safety and efficacy of NOX-A12 three additional arms combining NOX-A12 with: A. radiotherapy in patients with complete tumor resection; B. radiotherapy and bevacizumab; and C. radiotherapy and pembrolizumab.

About the OPTIMUS Study

OPTIMUS (NCT04901741) is *TME Pharma's* planned open-label two-arm Phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients.

Disclaimer

Translations of any press release into languages other than English are intended solely as a convenience to the non-English-reading audience. The company has attempted to provide an accurate translation of the original text in English, but due to the nuances in translating into another language, slight differences may exist. This press release includes certain disclosures that contain "forward-looking statements." Forward-looking statements are based on *TME Pharma's* current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials and the timing of and *TME Pharma's* ability to obtain regulatory approvals for NOX-A12 as well as any other drug candidates. Forward-looking statements contained in this announcement are made as of this date, and *TME Pharma* undertakes no duty to update such information except as required under applicable law.